EDESA BIOTECH, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets
EDESA BIOTECH, INC. (EDSA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets of $42.05 thousand as of 2020-09-30, per its 10-K filed 2020-12-07.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets · last filed 2020-12-07
- 2020-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets $42.05K.
- 2019-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets $42.05K.
- 2019-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets $42.05K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets |
|---|---|
| 2020-09-30 | $42.05K 10-K · filed 2020-12-07 |
| 2019-09-30 | $42.05K 10-KT · filed 2019-12-12 |
| 2019-06-30 | $42.05K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |